Optimizing PNH Management with Iptacopan: Insights from Real-World Practice (ICBMT 2026) - Oct 8, 2026 - Abstract #LS03; Pres time: Sep 17, 2026; 12:00 PM - 12:40 PM; Location: Room D(2F); "In this presentation, recent clinical trial and real-world evidence for iptacopan will be reviewed together with representative cases from clinical practice. Particular emphasis will be placed on recognizing residual hemolysis despite apparently adequate C5 inhibition, identifying patients who may benefit from proximal complement inhibition, and integrating efficacy, safety, treatment convenience, and patient preference into individualized treatment decisions for PNH."
Clinical • Real-world • Real-world evidence • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Thrombosis
|